Trials / Completed
CompletedNCT06843460
A Clinical Study of MK-7962 in Healthy Chinese Participants (MK-7962-021)
A Single-Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Sotatercept (MK-7962) in Healthy Chinese Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The goal of this study is to learn about the safety of 2 different amounts of sotatercept and if healthy Chinese people tolerate them. The study will also measure what happens to sotatercept in a person's body over time (pharmacokinetic or PK study).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Sotatercept | Single subcutaneous injection |
| OTHER | Placebo | Single subcutaneous injection |
Timeline
- Start date
- 2023-11-22
- Primary completion
- 2024-05-21
- Completion
- 2024-05-21
- First posted
- 2025-02-25
- Last updated
- 2025-02-25
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06843460. Inclusion in this directory is not an endorsement.